Articles related to Pediatric Hematology/Oncology

FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.

A phase 3 randomized trial of 449 children with intracranial ependymoma found no significant event-free or overall survival benefit from adding maintenance chemotherapy after radiation, while molecular markers — particularly 1q gain and 6q loss — identified a high-risk posterior fossa subgroup with substantially worse outcomes.

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.